The Role Of Capsid Protein Nucleolar Localisation In Chikungunya Virus: Implications For Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$520,520.00
Summary
Chikungunya virus (CHIKV) is a globally widespread mosquito-borne alphavirus capable of causing considerable human morbidity and mortality. With no CHIKV vaccine or antiviral available this proposal aims to develop a live attenuated CHIKV vaccine, rationally designed by investigating the host cell nucleolar trafficking of CHIKV capsid protein. This vaccine has the potential to provide cross-protection against additional arthritogenic alphaviruses endemic to Australia such as Ross River virus.
Mosquito-borne alphaviruses such as Ross River and chikungunya viruses cause widespread epidemics and exert extreme pressure on the public health systems of affected regions. Alphaviruses spreads to joints and triggers a severe disease in those affected. There are no effective treatments or vaccines. The project will investigate virus-host interaction at the bite site. The outcome will be new knowledge to treat infection at the mosquito bite site to prevent joint disease.
Novel Insights Into The Pathobiology Of Alphavirus Infections
Funder
National Health and Medical Research Council
Funding Amount
$827,660.00
Summary
Infections with mosquito-borne viruses are increasing at an alarming rate worldwide. Ross River virus is endemic in parts of Australia, PNG and Pacific islands, while chikungunya virus is distributed globally and causes recurrent pandemics that involve millions of people. These viruses cause severe musculoskeletal disease for several months after infection. This project aims to establish how these viruses interact with the human host to cause disease and may provide a basis for new treatments.
Australian Centre For Research Excellence In Aboriginal Sexual Health And Blood Borne Viruses
Funder
National Health and Medical Research Council
Funding Amount
$2,496,848.00
Summary
Despite efforts to improve sexual health and blood borne virus outcomes for Aboriginal people over the last twenty years, this area lacks national coordination, has critical research gaps and requires a boost of research capacity to address the burden of diseases. This CRE will address research gaps, using novel, multidisciplinary methods and using unique research translation methods to ensure policy and practice benefits from the CRE outcomes.
Defining domains within Mycoplasma hyopneumoniae surface proteins that interact with host extracellular matrix: efficacy testing of candidate vaccines in swine. Over 90% of Australian commercial pig production facilities are affected by Mycoplasma hyopneumoniae, the causative agent of swine enzootic pneumonia. This disease causes economic losses in Australia of over $20 million per annum and up to $1 billion per annum in major swine rearing countries worldwide. This project will determine the p ....Defining domains within Mycoplasma hyopneumoniae surface proteins that interact with host extracellular matrix: efficacy testing of candidate vaccines in swine. Over 90% of Australian commercial pig production facilities are affected by Mycoplasma hyopneumoniae, the causative agent of swine enzootic pneumonia. This disease causes economic losses in Australia of over $20 million per annum and up to $1 billion per annum in major swine rearing countries worldwide. This project will determine the protective efficacy of new generation vaccines against M. hyopneumoniae, which aim to block the colonisation process and prevent disease .Read moreRead less
Identification and characterisation of Mycoplasma hyopneumoniae surface-molecules that interact with the host epithelium. Mycoplasma hyponeumoniae causes porcine enzootic pneumonia, a disease that significantly impacts swine production. Current vaccines are unable to prevent colonisation of the respiratory tract and are costly to produce and administer. The expression of microbial adhesins that mediate adherence to the extracellular matrix is considered the initial step in host colonisation for ....Identification and characterisation of Mycoplasma hyopneumoniae surface-molecules that interact with the host epithelium. Mycoplasma hyponeumoniae causes porcine enzootic pneumonia, a disease that significantly impacts swine production. Current vaccines are unable to prevent colonisation of the respiratory tract and are costly to produce and administer. The expression of microbial adhesins that mediate adherence to the extracellular matrix is considered the initial step in host colonisation for many bacterial pathogens. We propose to identify M. hyopneumoniae cell surface moleculaes that interact with components of the extracellular matrix. Targetting these cell surface molecules will lead to therapeutics that prevent disease and block colonisation, eventually eradicating the host pathogen from pig production facilities.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE200101832
Funder
Australian Research Council
Funding Amount
$425,941.00
Summary
Mechanisms of immune protection for infectious laryngotracheitis virus. This project aims to investigate the mechanisms of immune protection against infectious laryngotracheitis virus. This will be achieved by investigating the role of local and systemic immunity and the immune cells associated with long-term protection against disease. The mechanisms of protection against this virus remain unknown which impairs the development of efficacious vaccines. Expected outcomes of this project are a mor ....Mechanisms of immune protection for infectious laryngotracheitis virus. This project aims to investigate the mechanisms of immune protection against infectious laryngotracheitis virus. This will be achieved by investigating the role of local and systemic immunity and the immune cells associated with long-term protection against disease. The mechanisms of protection against this virus remain unknown which impairs the development of efficacious vaccines. Expected outcomes of this project are a more rational approach to vaccination resulting in the generation of more effective and safer vaccination strategies that should benefit our important poultry industry. Additionally, the new methodologies and knowledge on mucosal immune markers could be utilised for the study of other pathogens.Read moreRead less
New antiparasitics to protect Australian livestock. There is an urgent need for new antiparasitics to treat multi-drug resistant livestock infections. This project aims to explore the bacteria and fungi present in the microbiomes of heavily infected sheep faeces and pastures, challenging them with environmental cues, including those from associated parasites, to stimulate production of defensive chemicals hidden deep within their genomes. Enabled by an integrated pipeline of high throughput anal ....New antiparasitics to protect Australian livestock. There is an urgent need for new antiparasitics to treat multi-drug resistant livestock infections. This project aims to explore the bacteria and fungi present in the microbiomes of heavily infected sheep faeces and pastures, challenging them with environmental cues, including those from associated parasites, to stimulate production of defensive chemicals hidden deep within their genomes. Enabled by an integrated pipeline of high throughput analytical cultivation, molecular networking, and chemical and biological analyses, expected outcomes include an enhanced ability to explore and exploit valuable chemistry hidden within microbial genomes, leading to the discovery of new classes of natural antiparasitic to safeguard livestock.
Read moreRead less
Targeting Fungal Phospholipid Metabolism For Antifungal Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$828,557.00
Summary
Invasive fungal infections are a serious and escalating health problem. They cause severe disease with a high death rate and are very costly to the health system. New antifungal drugs with novel properties are needed now because there are problems with current drugs. This project aims to develop potent new antifungal drugs that are effective in many fungal diseases and are well-tolerated.